One of the biggest reasons cancer immunotherapy fails is a phenomenon called T-cell exhaustion. The immune system's killer cells — our body's most powerful weapon against tumours — eventually wear out, becoming dysfunctional and unable to fight back. It has been a frustrating wall for oncologists.
Now, scientists from the Salk Institute for Biological Studies, UNC Lineberger Comprehensive Cancer Center, and UC San Diego have found the molecular switches that cause exhaustion — and shown that flipping them off can restore T-cells to full fighting strength.
The culprits are two previously unknown transcription factors: ZSCAN20 and JDP2.
By building a detailed genetic atlas of CD8+ T-cell states — mapping how these killer cells change as they become exhausted — the team pinpointed exactly which genes activate during burnout. When ZSCAN20 and JDP2 are active, they push T-cells into a dysfunctional, exhausted state. When those genes are disabled, the T-cells regain their tumour-killing capacity. Crucially, they also maintain long-term immune memory — meaning they stay effective rather than simply burning out faster.
'This challenges the previous assumption that immune exhaustion is an unavoidable consequence of extended immune activity,' the researchers noted in their published findings.
The breakthrough matters enormously for the future of cancer treatment:
— CAR T-cell therapy, which engineers a patient's own T-cells to target cancer, has had spectacular results in blood cancers but struggled against solid tumours partly because of exhaustion. Removing ZSCAN20 and JDP2 could make these engineered cells far more durable.
— Checkpoint inhibitors — drugs like pembrolizumab that remove the 'brakes' on exhausted T-cells — might work better or last longer when combined with therapies targeting these genes.
— Adoptive cell transfer, where tumour-fighting T-cells are grown in the lab and infused back into patients, could become dramatically more effective with T-cells engineered to resist burnout.
The implications stretch beyond cancer. T-cell exhaustion also limits the immune system's ability to fight HIV, tuberculosis, and other chronic infections where sustained immune activity is required.
The research, published in March 2026, provides what the team calls a 'blueprint for designing T-cells to kill' — a practical roadmap for the next generation of immune therapies.
In the fight against cancer, the immune system has always been our most powerful potential ally. Scientists just found a way to keep it from giving up. 🧬
*Sources: Salk Institute · UNC Lineberger Comprehensive Cancer Center · ScienceDaily · SciTechDaily*
